Resources
2 Results (showing 1 - 2)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 10/27/2023 (updated 3/28/2024)
While each state faces unique challenges in distributing opioid settlement funding, they also share many common priorities for settlements and other statewide efforts to address the opioid and substance use crisis.
Why it matters: Opioid settlement funding provides a unique opportunity to address current gaps in the addiction care system as a whole.
Posted 10/27/2023 (updated 3/28/2024)
As announced by the Substance Abuse and Mental Health Services Administration in January 2023, clinicians no longer need a federal waiver to prescribe buprenorphine for treatment of opioid use disorder. Clinicians will still be required to register with the federal Drug Enforcement Agency (DEA) to prescribe controlled medications. On June 27, the DEA began to require that registration applicants – both new and renewing – affirm they have completed a new, one-time, eight-hour training.